Theranostic in patients with recurring  Glioblastoma Multiforme (GBM): <sup>64</sup>CuCl<sub>2</sub> — ASN Events
  1. Schedule
  2. Conference Breakfast: Moderated Poster Walk - Novel Theranostics
  3. Theranostic in patients with recurring  Glioblastoma Multiforme (GBM): 64CuCl2

Theranostic in patients with recurring  Glioblastoma Multiforme (GBM): 64CuCl2 (#124)

Gianluca Valentini 1 , Paola Panichelli 1 , Carlo Villano 2 , Andrea Bruno 3 , Francesco Barbato 4 , Gioia Pigotti 1 , Beatrice Giacobbi 1
  1. A.C.O.M. SrL, Montecosaro , Italy
  2. Ospedale Civile "Spirito Santo", Pescara, Italy
  3. ASST Papa Giovanni XXIII , Bergamo, Italy
  4. Centro CMO, Napoli, Italy

Aim:to evaluate 64CuCl2 as theranostic radiopharmaceutical in recurring GBM after surgery. 

Introduction:Panichelli* (2016) described the diagnostic use of 64CuCl2 in GBM.Ferrari** (2015) demonstrated the therapeutic effect of 64CuCl2 in mice with GBM xenografts in single and fractionated dose method.In our laboratory we found in vitro(cellular line U-87 MG)the killer dose for a 50 million cells culture (minimum dose of 1 Bq/cell; data not published). 

Method:6 patients (December 2014-June 2015) with MRI evidence of recurring GBM were studied with 64CuCl2 PET/CT at 1,3,24 hours after i.v. injection of 13MBq/kg.Standard uptake values (SUVs) were calculated and absorbed radiation doses estimated (Olinda/Exm software).This dosimetric analysis allowed the calculation of the personalized dose treatment considering both the tumour volume (coregistered PET/CT) and the dose target for GBM as in vitro tested (1 Bq/cell).Subsequently,we performed treatment plan fractionating the total dose in 4-8 weeks (one injection each week).The results were controlled after the first month with PET/CT and MRI.PET/CT study was repeated after 2 months,than MRI was repeated every 3 months for 1 year.Blood samples were collected in all patients to evaluate marrow,hepatic and renal function (10 days from the end of treatment and after 3,6,12 months).Clinical evaluation was performed by the neurologist for the entire period of observation. 

Results:all patients are still alive 1 year after the end of the treatment,demonstrating a significant clinical improvement with any toxicity or hematological alterations,particularly for the liver, a critic organ.MRI showed in 4 patients a significative reduction of the global volume of the lesion (30%),than in 2 the lesion volume was stabilized but with different density. 

Conclusion:64CuCl2 seems a very promising theranostic radiopharmaceutical in treatment of recurring GBM.The real clinical role of 64CuCl2 needs a prolonged evaluation in order to calculate the overall survival.

*Cancer Biother Radiopharm,2016; ** Biomed Research Interational,2015